Articles

Quick View: BMS’s Acquisition Of Karuna Therapeutics Will Support Its Growing CNS Portfolio

Pharmaceuticals / United States / Fri 29 Dec, 2023

The Latest: On December 22 2023, Bristol Myers Squibb (BMS) announced plans to acquire Karuna Therapeutics, a central nervous system (CNS) company that specialises in developing therapeutics for psychiatric and neurological disorders, including schizophrenia and Alzheimer’s disease (AD) psychosis. The deal is worth a total of USD14bn.

Implicatio

Read More
Download Indicator Summary
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Download Now
 

Thank you. Your download link will be emailed to you shortly.

Clearbit Form
 

Thank you. Your download link will be emailed to you shortly.